Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER-OSA 2: Berobenatide in Obstructive Sleep Apnea and Overweight/Obesity
NCT07881757Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea (OSA), obesity and Overweight comparing Berobenatide with Placebo (2 arms). Primary endpoint: Apnea-Hypopnea Index at 52 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
berobenatide
03
Conditions
obstructive sleep apnea (OSA)obesityOverweight
Beyond the preview
Go deeper on NCT07881757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881757.